Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • ObservationalCompleted with results Location: USA

    BONUS: Baby Observational and Nutritional Study , protocol number BONUS-IP-11, BONUS10K0

    This study took place at multiple care centres across the US. It aimed to gain a better understanding of the factors that interfere with good growth in infants with CF.

    • Age:

      Less than 15 weeks

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      9

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis , protocol number Novartis CTBM100C2401

    This open-label study assessed the long term safety of tobramycin inhalation powder (TIP) in people with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 75%

    • Number of Visits:

      9

    • Length of Participation:

      52 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveClosed to enrollment Location: USA

    Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study , protocol number Novartis CTBM100C2401E1

    The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 75%

    • Number of Visits:

      8

    • Length of Participation:

      48 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: USA

    Phase 4 TOBI Podhaler observational study , protocol number Novartis CTBM100C2407

    This study is taking place at multiple care centres across the US. It will look at the effectiveness and long term safety of the TOBI Podhaler and other FDA-approved inhaled antipseudomonal drugs.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 80%

    • Number of Visits:

      22

    • Length of Participation:

      60 months

    Contact us about this clinical Trial >
  • ObservationalCompleted with results Location: USA

    TOBI Podhaler Usability Study , protocol number Novartis CTBM100C2412

    This study took place at multiple care centres across the US. It looked at how well people are able to understand and follow the TOBI Podhaler instructions for use.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% or greater

    • Number of Visits:

      2

    • Length of Participation:

      1 month

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled , protocol number Novartis CTBM100CUS03

    This open-label study tested the effectiveness and safety of two different dose regimens of Tobramycin Inhalation Powder (TIP) for the treatment of Pseudomonas aeruginosa.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 80%

    • Number of Visits:

      9

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryEnrolling Location: USA

    Phase 2 study of CTX-4430 in people with CF (EMPIRE) , protocol number Celtaxsys CTX-4430

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug CTX-4430 and will use a placebo control.

    • Age:

      18 Years to 30 Years

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      50% or greater

    • Number of Visits:

      15

    • Length of Participation:

      1 year

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    Persistent Methicillin Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture , protocol number DASENB10AO, PMEP11K1, JENNIN16K0

    This study will look at the safety and effectiveness of a 28-day course of vancomycin for inhalation in getting rid of the bacteria, Methicillan Resistant Staphylococcus Aureus (MRSA) from the respiratory tract of people with CF and persistent MRSA infection.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      7

    • Length of Participation:

      8 months

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    STOP: Standardised Treatment of Pulmonary Exacerbations Pilot Study , protocol number FLUME13A1

    This study took place at multiple care centres across the US. The goal of the study was to better understand current treatment practices for pulmonary exacerbations and whether the CF Registry can be used for this type of study.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      4

    • Length of Participation:

      28 days

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    IGNITE: Safety and effectiveness of gallium nitrate in adults with cystic fibrosis , protocol number GALLIUM-IP-13

    This study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of IV gallium nitrate in adults with cystic fibrosis who are chronically infected with Pseudomonas aeruginosa.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% or greater

    • Number of Visits:

      5

    • Length of Participation:

      63 days

    Contact us about this clinical Trial >
  • Displaying results 91-100 (of 142)
     |<  <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >  >|